212 related articles for article (PubMed ID: 37451904)
1. Dose imbalance of DYRK1A kinase causes systemic progeroid status in Down syndrome by increasing the un-repaired DNA damage and reducing LaminB1 levels.
Murray A; Gough G; Cindrić A; Vučković F; Koschut D; Borelli V; Petrović DJ; Bekavac A; Plećaš A; Hribljan V; Brunmeir R; Jurić J; Pučić-Baković M; Slana A; Deriš H; Frkatović A; Groet J; O'Brien NL; Chen HY; Yeap YJ; Delom F; Havlicek S; Gammon L; Hamburg S; Startin C; D'Souza H; Mitrečić D; Kero M; Odak L; Krušlin B; Krsnik Ž; Kostović I; Foo JN; Loh YH; Dunn NR; de la Luna S; Spector T; Barišić I; Thomas MSC; Strydom A; Franceschi C; Lauc G; Krištić J; Alić I; Nižetić D
EBioMedicine; 2023 Aug; 94():104692. PubMed ID: 37451904
[TBL] [Abstract][Full Text] [Related]
2. Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
Çağlayan ES
Cell Biol Int; 2016 Dec; 40(12):1256-1270. PubMed ID: 27743462
[TBL] [Abstract][Full Text] [Related]
3. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome.
Canzonetta C; Mulligan C; Deutsch S; Ruf S; O'Doherty A; Lyle R; Borel C; Lin-Marq N; Delom F; Groet J; Schnappauf F; De Vita S; Averill S; Priestley JV; Martin JE; Shipley J; Denyer G; Epstein CJ; Fillat C; Estivill X; Tybulewicz VL; Fisher EM; Antonarakis SE; Nizetic D
Am J Hum Genet; 2008 Sep; 83(3):388-400. PubMed ID: 18771760
[TBL] [Abstract][Full Text] [Related]
4. Brief report: isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration.
Murray A; Letourneau A; Canzonetta C; Stathaki E; Gimelli S; Sloan-Bena F; Abrehart R; Goh P; Lim S; Baldo C; Dagna-Bricarelli F; Hannan S; Mortensen M; Ballard D; Syndercombe Court D; Fusaki N; Hasegawa M; Smart TG; Bishop C; Antonarakis SE; Groet J; Nizetic D
Stem Cells; 2015 Jun; 33(6):2077-84. PubMed ID: 25694335
[TBL] [Abstract][Full Text] [Related]
5. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
[TBL] [Abstract][Full Text] [Related]
6. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
[TBL] [Abstract][Full Text] [Related]
7. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.
Toiber D; Azkona G; Ben-Ari S; Torán N; Soreq H; Dierssen M
Neurobiol Dis; 2010 Oct; 40(1):348-59. PubMed ID: 20600907
[TBL] [Abstract][Full Text] [Related]
8. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
Hijazi M; Fillat C; Medina JM; Velasco A
Exp Neurol; 2013 Jan; 239():229-34. PubMed ID: 23124096
[TBL] [Abstract][Full Text] [Related]
10. Isogenic pairs of induced-pluripotent stem-derived endothelial cells identify DYRK1A/PPARG/EGR1 pathway is responsible for Down syndrome-associated pulmonary hypertension.
Suginobe H; Ishida H; Ishii Y; Ueda K; Yoshihara C; Ueyama A; Wang R; Tsuru H; Hashimoto K; Hirose M; Ishii R; Narita J; Kitabatake Y; Ozono K
Hum Mol Genet; 2023 Dec; 33(1):78-90. PubMed ID: 37792788
[TBL] [Abstract][Full Text] [Related]
11. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
[TBL] [Abstract][Full Text] [Related]
12. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
13. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
[TBL] [Abstract][Full Text] [Related]
14. DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.
Najas S; Arranz J; Lochhead PA; Ashford AL; Oxley D; Delabar JM; Cook SJ; Barallobre MJ; Arbonés ML
EBioMedicine; 2015; 2(2):120-34. PubMed ID: 26137553
[TBL] [Abstract][Full Text] [Related]
15. Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model.
Hawley LE; Stringer M; Deal AJ; Folz A; Goodlett CR; Roper RJ
Neurobiol Dis; 2024 Jan; 190():106359. PubMed ID: 37992782
[TBL] [Abstract][Full Text] [Related]
16. Craniofacial dysmorphology in Down syndrome is caused by increased dosage of Dyrk1a and at least three other genes.
Redhead Y; Gibbins D; Lana-Elola E; Watson-Scales S; Dobson L; Krause M; Liu KJ; Fisher EMC; Green JBA; Tybulewicz VLJ
Development; 2023 Apr; 150(8):. PubMed ID: 37102702
[TBL] [Abstract][Full Text] [Related]
17. A patient with partial trisomy 21 and 7q deletion expresses mild Down syndrome phenotype.
Papoulidis I; Papageorgiou E; Siomou E; Oikonomidou E; Thomaidis L; Vetro A; Zuffardi O; Liehr T; Manolakos E; Vassilis P
Gene; 2014 Feb; 536(2):441-3. PubMed ID: 24334122
[TBL] [Abstract][Full Text] [Related]
18. A human isogenic iPSC-derived cell line panel identifies major regulators of aberrant astrocyte proliferation in Down syndrome.
Kawatani K; Nambara T; Nawa N; Yoshimatsu H; Kusakabe H; Hirata K; Tanave A; Sumiyama K; Banno K; Taniguchi H; Arahori H; Ozono K; Kitabatake Y
Commun Biol; 2021 Jun; 4(1):730. PubMed ID: 34127780
[TBL] [Abstract][Full Text] [Related]
19. Generation of two induced pluripotent stem cell lines from patients with Down syndrome.
Zhu W; Liu W; Yu R; Manning M; Waran Romfh A; Wu JC
Stem Cell Res; 2023 Oct; 72():103204. PubMed ID: 37734318
[TBL] [Abstract][Full Text] [Related]
20. [Molecular Mechanism Underlying Abnormal Differentiation of Neural Progenitor Cells in the Developing Down Syndrome Brain].
Kurabayashi N; Sanada K
Yakugaku Zasshi; 2017; 137(7):795-800. PubMed ID: 28674289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
